Modern St. Petersburg medspa treatment room with two RF microneedling devices on stainless carts in warm afternoon sunlight

We get this question three times a week

A patient sits down for a consult and asks, "Should I do Morpheus8 or Sylfirm X?" We hear it so often we've stopped being surprised. Most weeks we hear it from someone who has already booked elsewhere, cancelled, and come in for a second opinion — confused not because the technology is unclear, but because every clinic they've called told them their device was the right one.

That makes sense. Most clinics only own one of the two. When the only tool you have is Morpheus8, every patient looks like a Morpheus8 patient. When the only tool you have is Sylfirm X, every patient looks like a Sylfirm X patient. Neither answer is dishonest, exactly — it's just the answer that fits the inventory.

We're in an unusual position. We own both devices and we train on both. So we have no economic reason to push you toward one or the other, which gave us the room to do something most clinics can't: write down the actual decision logic we use, so you can audit it before you book.

The honest one-line answer

We offer both devices. The wrong choice between them costs you somewhere between $1,200 and $2,400 in sessions that won't get you where you want to go — and in a small number of cases (Fitz IV–VI skin tones, active melasma) the wrong choice carries clinical risk, not just wasted money. The routing logic below is what we use internally. It's published here so you can audit it before you book.

The short answer, before we unpack it

If you want the framework without the explanation first, here it is:

If your primary concern is… And your skin profile is… The first-line device for you is Why
Skin laxity, jawline definition, mild jowls Fitz I–III Morpheus8 Variable depth + tissue remodeling at depths SylX cannot reach
Melasma, post-inflammatory hyperpigmentation, vascular sensitivity Any Fitz, especially IV–VI Sylfirm X Pulsed-Wave mode targets chromophores; safer PIH profile in skin of color
General fine lines, texture, large pores, mild acne scarring Fitz I–III Either — usually whichever the clinic schedules first Same baseline mechanism; differences are small at superficial depth
Acne scarring + dyschromia (color irregularity) combined Fitz IV–VI Sylfirm X The pigment safety profile outweighs the depth advantage
Lower-face contour + subdermal tissue change Any Fitz Morpheus8 Body (a depth-different variant of M8) Sylfirm X is not designed for subdermal tissue work

If your situation isn't in that table, the rest of this article is for you.

What both devices actually do

Both Morpheus8 and Sylfirm X are radiofrequency microneedling devices. That means each one inserts very thin needles into your skin, then delivers a controlled dose of radiofrequency energy through those needles. The needles by themselves cause a small mechanical injury. The radiofrequency energy adds a controlled thermal injury at a specific depth. Your body's response to that controlled injury is the actual treatment: it produces new collagen and elastin as it heals, which is what tightens and remodels skin over the next several months.

That mechanism is the same in both devices. The first thing to understand about Morpheus8 versus Sylfirm X is that 80% of the work — collagen induction at superficial-to-mid dermal depth — is identical between them. Most of the marketing copy that compares one to the other is comparing the remaining 20%. Useful, but not the whole picture.

Two operational notes that matter once we get into specifics:

First, "depth" is not a single number. Both devices ship with multiple needle cartridges, and each cartridge has its own maximum depth setting. A statement like "Morpheus8 goes to 4 mm" or "to 7 mm" depends entirely on which cartridge is loaded. We pick the cartridge based on what we're treating, not based on hitting a number.

Second, FDA clearance language is narrower than vendor marketing. Both devices are cleared by the FDA as radiofrequency microneedling devices — for electrocoagulation and hemostasis of soft tissue. They are not, in regulatory terms, cleared as treatments for "melasma" or "acne scarring" or "skin laxity." When clinical evidence supports those uses, providers use the devices off-label, which is normal and legal in medicine. We mention this so you can tell the difference between an FDA-cleared indication and a marketing claim.

Where they structurally differ

Cross-section diagram: variable-depth radiofrequency microneedling on the left, continuous wave versus pulsed wave RF profiles on the right

The real differences live in two places: depth control and pulse profile.

Morpheus8 (Inmode): Bipolar radiofrequency. The signature feature is depth-controlled cartridges that reach progressively deeper layers of skin and the tissue immediately beneath it. The deeper cartridges — particularly on the Morpheus8 Body platform — are designed to remodel subdermal tissue, not just the dermis. The independent evidence is strongest for skin and dermal remodeling; the subdermal claims are supported by histology but the controlled imaging evidence is thinner than the marketing implies. We talk to patients about "remodeling subdermal tissue" rather than "melting fat," because that's what the data actually supports.

Sylfirm X (Viol): Bipolar radiofrequency with two distinct delivery modes — Continuous Wave (similar in effect to traditional RF microneedling) and Pulsed Wave (the differentiator). Pulsed Wave is shorter, more selective, and built to target chromophores — the pigment and vasculature inside the skin — without delivering as much bulk thermal energy to surrounding tissue. That profile is what makes Sylfirm X the device of choice for melasma, post-inflammatory hyperpigmentation, rosacea, and patients with skin of color (Fitzpatrick IV–VI) who would be at higher PIH risk with conventional RF microneedling.

The evidence base for Sylfirm X on melasma is favorable but smaller than the manufacturer's marketing reads — most of the published literature comes from Korean dermatology with small patient counts. We treat melasma conservatively: lower energy, fewer passes, longer intervals, with strict sun-avoidance protocols. We tell patients honestly that this is an evolving evidence area.

The decision framework, unpacked

Decision routing flowchart: five patient archetypes branching from a central question to two device endpoints

If you want a short version: identify what's primarily driving you to consider treatment, then check your skin profile. The combination of those two signals routes you cleanly most of the time.

Rule 1 — Skin laxity is your top concern, and your skin is Fitzpatrick I–III. Morpheus8 is the first-line choice. Variable-depth tissue remodeling is what it was designed for. Sylfirm X can produce some tightening effect, but if structure is what's driving you, you're using the wrong tool to start.

Rule 2 — Pigment is your top concern. This includes melasma, post-inflammatory hyperpigmentation from old acne, or sun-driven irregular pigmentation. Sylfirm X is the first-line choice. The Pulsed-Wave mode is the only feature in either device specifically built for chromophore-selective work. We treat melasma conservatively in either case, but Sylfirm X is the safer and more effective entry point.

Rule 3 — Your skin is Fitzpatrick IV–VI. Default to Sylfirm X unless there is a strong clinical reason to use Morpheus8. This rule is about safety, not effectiveness. Conventional RF microneedling at higher energies can trigger post-inflammatory hyperpigmentation in darker skin tones; Sylfirm X's pulse profile is structurally better suited to higher Fitzpatrick types. If we do recommend Morpheus8 for a Fitzpatrick IV–VI patient — usually because of a specific depth requirement we can't address with Sylfirm X — we discuss the PIH-risk tradeoff explicitly, run conservative settings, and stage the protocol over more sessions.

Rule 4 — Your top concern is texture, fine lines, large pores, or general "improve my skin's quality." Either device works. At the superficial dermal depths where these results live, the two devices produce similar outcomes. We schedule patients in this category based on calendar availability, not technology, and the clinical outcomes are statistically indistinguishable.

Rule 5 — Your concern includes lower-face contouring or subdermal tissue change. This is Morpheus8 Body territory. The deeper-tip platform is the only one in our toolkit designed for tissue work at that depth. Sylfirm X is not designed for this use case; using it instead would be wrong-tool/wrong-job.

Rule 6 — Combined concerns where one is pigment-related and you're Fitzpatrick IV–VI. Default to Sylfirm X first, address the secondary concern separately if needed. Trying to address everything with one device in this case usually leaves you with a compromise treatment that didn't quite solve any of your concerns optimally.

What changes if you pick wrong

In the median case, picking the "wrong" device just means you spend money on sessions that move you 60% of the way toward your goal instead of 100%. That's the cost we mentioned at the top: $1,200 to $2,400 for a typical 3-session package that wasn't matched to your situation. You will look better. You won't look as much better as a correctly-matched protocol would have made you look.

In a smaller number of cases the cost is clinical, not just financial. Running standard Morpheus8 protocols on a Fitzpatrick V patient with active or recent melasma raises the risk of post-inflammatory hyperpigmentation — a darkening of the treated area that can be slow to resolve and harder to treat than the original pigment problem. That's the case where the device matching isn't a preference, it's a safety call. It's also why we screen Fitzpatrick type and pigmentation history before quoting anyone a protocol, not after.

Cost and sessions, with the actual numbers

We get pushback for publishing prices publicly. Other clinics in St. Pete don't. We do it anyway because the rest of the medspa internet has trained patients to expect "call for pricing," and "call for pricing" is usually a euphemism for "we want the chance to talk you up before you decide."

For context, the ranges below are typical of professional-grade RF microneedling in the Tampa Bay market in 2026. Our current menu is at the price menu page — the numbers there are authoritative if anything below has drifted.

Treatment Per-session range Typical package Notes
Morpheus8 (face) $1,200 – $2,400 Series of 3, scheduled 4–6 weeks apart Final result evaluated at the 90-day mark after the third session
Sylfirm X $1,200 – $2,400 Series of 3 (general) or 4–6 (melasma protocol) Melasma protocols often require longer intervals + maintenance
Morpheus8 Body $2,000 – $3,500 per area 3 sessions per treatment area Depends on area size + depth selected

If the up-front package is the obstacle, our payment plans split treatment over financed monthly installments. That's worth mentioning here because cost-versus-readiness is often the actual decision a patient is wrestling with — not Morpheus8 versus Sylfirm X.

Recovery, day by day

Horizontal recovery timeline with color gradient from pink at Day 0 to sage at Day 90, marked with eight milestone glyphs

Most patients are surprised at how mild the recovery is. Day-by-day, here's what to plan for. (We're describing typical face protocols. Body protocols and aggressive melasma settings can extend each phase by a day or two.)

The Florida sun question

Tampa Bay sun is the thing patients underestimate most. Two specifics matter for RF microneedling recovery here that don't matter as much in other markets.

The first is direct UV in the post-treatment window. The skin is more vulnerable to pigment changes for several weeks after treatment, not just the first few days. SPF 30+ (we prefer 50+) is non-negotiable, but the more important behavior change is staying out of the noon-to-3-pm window entirely for the first 7–10 days. A boat weekend three days after treatment is the single most common reason a patient sees less-than-ideal pigment results.

The second is humidity affecting aftercare. Florida humidity affects how moisturizer behaves on a freshly-treated dermis. We give patients specific product recommendations at consult, but the short version: lean lighter, layer more often, avoid occlusive heavy products in the first 72 hours.

Patients with melasma — Pulsed Wave Sylfirm X protocols especially — need to be even more strict, because the Florida-sun-plus-melasma combination is the exact condition the device is designed to address. Re-aggravating it post-treatment defeats the purpose.

How we make the call in our clinic

Here is the decision tree we actually use during a consult. We are publishing it because the people most likely to read this article are the people considering booking elsewhere too — and we want you to be able to read another clinic's recommendation through this lens.

  1. Identify primary concern. Pigment, laxity, texture, scarring, contouring, or combined.
  2. Identify Fitzpatrick type. Self-reported during intake, confirmed during exam.
  3. Identify history flags. Active or recent melasma, post-inflammatory hyperpigmentation history, isotretinoin within the last several months, active acne, pregnancy/breastfeeding, immunosuppression, history of keloid scarring.
  4. Apply the rules above to route to a first-line device.
  5. Re-examine the routing in light of the history flags. Some flags don't change the routing; others (active melasma, history of keloid scarring, recent isotretinoin) change the timeline, the protocol, or sometimes the decision to treat at all.
  6. Discuss the alternative explicitly with the patient. If we recommend Morpheus8, we explain why we didn't recommend Sylfirm X. If we recommend Sylfirm X, we explain why we didn't recommend Morpheus8. A patient who understands the routing makes better decisions about whether to proceed.
  7. Estimate the protocol. Number of sessions, interval, cost, expected outcome window. The honest answer here is often longer than the patient expects — collagen remodeling is slow biology.

This is what an honest routing consult looks like. It does not replace a clinical exam, but it gives you a way to evaluate whether a consult you sit through anywhere — including ours — is being run on routing logic or on inventory logic.

When we'd say "neither right now"

Some patients should not be treated with either device at the current visit. Most of these are timing issues, not permanent disqualifications.

That last one is the actual test of whether a clinic is being honest with you. A clinic that has never told a patient "what you actually want is surgery, not us" is probably not telling you the whole truth about what RF microneedling can do.

Frequently asked questions

How painful is it? With topical numbing applied for 30–45 minutes prior, most patients describe the treatment as tolerable — a vibrating heat sensation rather than sharp pain. Body protocols and deeper face settings can feel more intense; we adjust as we go.

How many sessions will I actually need? Most face protocols are a series of three, scheduled 4–6 weeks apart, with the result evaluated at 90 days after the final session. Melasma protocols often require 4–6 sessions and longer intervals. Body protocols depend on the area.

When will I see results? Early skin-quality changes are visible in the first two weeks. Structural and tightening changes build over 8–12 weeks. The full result is evaluated at the 90-day mark after the final session.

Can I combine Morpheus8 and Sylfirm X? Rarely a clinical necessity. The marketing case for combining them is stronger than the evidence case. We do occasionally use both in the same patient — for example, addressing pigment with Sylfirm X first and then doing structural work with Morpheus8 later — but as sequenced phases of care, not as a "more is better" stack.

Are there permanent risks? The most common adverse events are transient: pinkness, swelling, minor pinpoint bleeding, occasional temporary darkening or lightening of treated areas. Rare but more serious risks include scarring, infection, and persistent pigment changes. We screen for the risk factors associated with each before recommending treatment.

What about results after one session? Initial skin-quality changes are real and visible after one session. Structural results — the kind that justify the cost — are a cumulative effect of the full series.

Book a routing consult

If you've read this far, you don't need a sales pitch. You need a conversation that actually looks at your skin, your concerns, and your history, and produces a recommendation that fits you, not our schedule. That's what a consultation at St. Pete Wellness MedSpa is — a routing conversation, not a closing call.

If we recommend Morpheus8, you'll know why. If we recommend Sylfirm X, you'll know why. If we recommend neither — or recommend that you see a different kind of provider entirely — you'll know that too.

The honest decision is the one made with the framework above, not against it.

External citations

  1. Inmode — Morpheus8 device information (manufacturer) — manufacturer source; marketing claims are clearly identified as such
  2. Viol — Sylfirm X device information (manufacturer) — manufacturer source; marketing claims are clearly identified as such
  3. FDA 510(k) device clearance database — for independent verification of device clearance scope
  4. American Society for Dermatologic Surgery — radiofrequency microneedling patient guide — patient-focused independent source
  5. American Academy of Dermatology — what to know before microneedling — independent patient education
  6. PubMed — recent meta-analyses of RF microneedling outcomes — independent clinical literature

Internal references on this site

FDA disclosure note: References in this article to "FDA-cleared" describe device clearances. Specific clinical uses described above may be off-label, consistent with standard medical practice. This article is educational and is not a substitute for medical advice from a licensed provider.